SEC Tracker
Get the app

Acelrx Pharmaceuticals TLPH

Acelrx Pharmaceuticals: ends a material agreement and reports an exchange listing deficiency notice

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Ends a material agreement (1.02)
  • Reports an exchange listing deficiency notice (3.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Acelrx Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biovie BIVI public float $8M, Dec 31, 2025
  2. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
  3. GT Biopharma GTBP public float $9M, Jun 30, 2025
  4. Orgenesis ORGS public float $8M, Jun 30, 2025
  5. TherapeuticsMD TXMD public float $9M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.